While our immunohistochemical and exome sequencing findings point to MAPK pathway activation in SCOs, the finding of two MEN1 mutations in cases 3A and 3B suggests that biallelic inactivation of MEN1 may be a second mechanism underlying neoplasia in SCO. This evidence concerns the gene MEN1 and small cell osteogenic sarcoma.